Related Experiment Videos
Chlamydia pneumoniae and atherosclerosis: current state and future prospectives
International Journal of Immunopathology and Pharmacology
|March 25, 2009
Summary
Chlamydia pneumoniae infections may contribute to atherosclerosis by persisting in tissues and causing chronic inflammation. This review updates research on the bacterium's role in cardiovascular disease pathogenesis.
Area of Science:
- Microbiology
- Immunology
- Cardiovascular Research
Background:
- Chlamydia pneumoniae is a common cause of respiratory infections.
- Emerging evidence links C. pneumoniae infection to atherosclerosis development.
- The bacterium's persistence and inflammatory potential are key to its role.
Discussion:
- C. pneumoniae disseminates from the lungs via peripheral blood cells.
- It infects arterial cells (endothelial, smooth muscle, monocytes/macrophages).
- This infection promotes an inflammatory atherogenesis process.
Key Insights:
- Seroepidemiological, pathological, in vivo, and in vitro studies investigate the link.
- Clinical trials explore antibiotic treatments for C. pneumoniae-associated atherosclerosis.
- Recent insights highlight the bacterium's specific mechanisms in disease.
Outlook:
- Further research is needed to fully elucidate C. pneumoniae's causative role.
- Identifying therapeutic targets for C. pneumoniae in atherosclerosis is crucial.
- Future studies should focus on long-term persistence and inflammatory pathways.
Related Concept Videos
01:29Bacterial Phylum Chlamydiae
The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic of...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...